CD8A and neoplasm: These neoantigen-augmented iPSC cancer vaccines remarkably enhanced neoantigen-reactive CD8+ T cell responses and promoted the production of antitumor cytokines such as IFNγ and GzmB to eradicate tumor cells and decrease the risk of distant metastasis.